ArticlePoultry science2026
Molecular characterization, evolutionary dynamics, and pathogenic assessment of chicken infectious anemia virus isolates circulating in Egyptian poultry.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a result of its severe immunosuppressive nature, CIAV persists as a critical pathogen causing substantial economic concerns in global poultry production. The emergence of genetic variants and reports of suspected vaccine sub-optimal protection in Egyptian broiler flocks necessitates an urgent investigation of currently circulating strains. In this study, 165 samples were collected from six Egyptian governorates (2024-2025). PCR screening revealed 38 positive cases, and six isolates were selected for full-length sequencing of the VP1 and VP2 genes. Molecular analysis identified the isolates as Genotype II, showing significant genetic drift from Genotype I vaccinal strains. Key nonsynonymous mutations, notably H22Q in VP1, suggested potential antigenic escape, while the VP2 gene maintained 100% amino acid identity despite multiple silent mutations. Experimentally, the Genotype II isolate exhibited extreme virulence in SPF chickens; infected birds suffered from severe growth retardation (p < 0.0001) and profound lymphoid organ atrophy, with thymus weights dropping to 1.1 ± 0.07 g. Severe aplastic anemia was confirmed by a dramatic decline in PCV% (19.33 ± 1.45%) and pale, gelatinous bone marrow. Viral load quantification revealed massive replication in the thymus (9.5 Log₁₀) and bone marrow (9 Log₁₀), leading to a total collapse of humoral immunity, with antibody levels falling below the positivity threshold by the 4th week and reaching undetectable levels (S/P 0) by the 5th week post-infection. Histopathology corroborated these findings, showing systemic lymphocyte depletion and characteristic intranuclear inclusion bodies. These findings confirm the emergence of highly pathogenic Genotype II CIAV in Egypt. The ability of these variants to bypass existing immunity highlights the critical need for updating current vaccination strategies and implementing more robust biosecurity measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.